Optomed Reports Q3 2026 Financial Results

Optomed Oyj reported Q3 2026 revenue growth of 17.5% and positive EBITDA of €1.089 million. Its cash position improved to €6.985 million. Management expects revenue growth for the full year but said fourth-quarter performance will be critical following weaker results in the first half.